In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
about
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusIn vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolatesComparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.Emergence and management of drug-resistant enterococcal infections.Telavancin: a novel lipoglycopeptide antibiotic.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Novel antibiotics for the treatment of Staphylococcus aureus.Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.Tackling vancomycin-resistant bacteria with 'lipophilic-vancomycin-carbohydrate conjugates'.Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.Postantibiotic effects of telavancin against 16 gram-positive organisms.Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteersSpecificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women.Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004-2009).Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.
P2860
Q27027412-94FC4C48-F790-456A-9716-3CD140F82E30Q33876626-DDD957A4-AAB6-4B61-80DE-507F2B187226Q34309620-D487AF4B-3189-40E2-8DEB-0B6F25C85DF4Q37291346-A2600A1E-0B89-49EF-9DD2-05535A82972FQ37463589-FFB39003-8BA4-4C49-9167-242DF1E9CA59Q37955286-B78BB14D-A536-45A0-B4B0-B9FBA11F7CCCQ38263421-F6AA0C7A-4015-49DE-BEBB-4AAF4DAF5900Q39933945-6A8ACADC-271F-4C8E-8D1D-46FE36CA8E1FQ40335240-C36C7293-8CC6-4B9B-ACDA-222262F014A2Q41028154-197A28B0-45DD-4DB3-B939-BB11B3DA11BCQ41172790-808A7626-BFD6-4C1D-9DFB-8970F03364C5Q41686055-9B0D07C5-2481-48D9-BBA3-7881E1971F6EQ41687426-F43BC58B-0676-49BA-813D-F2A4926163AAQ41807543-B5FFDE11-CE5E-4349-B1DA-FC3B9F528340Q41999444-367C2976-55D2-41A5-8BDF-EAE43C69BB89Q42008120-C82D1E22-CE46-4F54-BD4B-706F7338E670Q42049579-05731D4F-E17F-4A9A-A6FC-991671E9D381Q42269882-F7BEAC19-37E0-4AA1-BA1D-D58D4F67356DQ42576977-C8EF9C4F-FC6D-4469-83F6-88ACEBB02707Q42738238-40B96985-0C70-445F-BEC0-027F201D8063Q42788454-645C1523-9A2B-4EF7-875E-4CC8940B0CA0Q42797044-D3885AEA-3B68-4ED3-BD30-8C1173EF84EAQ44935039-74E16441-85AD-42A7-8E2D-5F7153F547B8Q46489824-71FA7F3A-FABF-4E6E-9417-844F113CA5E2Q46556054-D3F2809A-7ED6-43E4-8421-DB5A030D6109Q49446863-DDBF45CD-5E64-4BA5-B99F-5BFF33380DA8
P2860
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
In vitro activity of telavanci ...... opean Surveillance Initiative.
@en
In vitro activity of telavanci ...... opean Surveillance Initiative.
@nl
type
label
In vitro activity of telavanci ...... opean Surveillance Initiative.
@en
In vitro activity of telavanci ...... opean Surveillance Initiative.
@nl
prefLabel
In vitro activity of telavanci ...... opean Surveillance Initiative.
@en
In vitro activity of telavanci ...... opean Surveillance Initiative.
@nl
P2093
P2860
P356
P1476
In vitro activity of telavanci ...... opean Surveillance Initiative.
@en
P2093
Bret M Benton
Chris Pillar
Clyde Thornsberry
Daniel F Sahm
Deborah C Draghi
Kevin M Krause
P2860
P304
P356
10.1093/JAC/DKN124
P407
P577
2008-04-19T00:00:00Z